Gyre Therapeutics (GYRE) Capital Expenditures Growth (3y) (2013 - 2026)
Powered by 
Analysis
Gyre Therapeutics (GYRE) Capital Expenditures Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 23.48% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 63.07% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -45.93% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -40.95% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 29.63% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 60.74% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 27.08% |
| 10 | Gyre Therapeutics | 691.38 Mn | 633.98 Mn | 26.90 Mn | -52.71% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -52.71% |
| Mar 31, 2026 | -53.25% |
| Sep 30, 2024 | 12.10% |
| Sep 30, 2023 | 116.32% |
| Jun 30, 2023 | 436.95% |
| Mar 31, 2023 | 367.95% |
| Mar 31, 2020 | 78.28% |
| Dec 31, 2019 | -26.16% |
| Sep 30, 2019 | -64.31% |
| Jun 30, 2019 | -40.70% |
| Mar 31, 2019 | -44.76% |
| Dec 31, 2018 | 21.32% |
| Dec 31, 2016 | 63.77% |
| Jun 30, 2016 | 120.23% |
| Mar 31, 2016 | 8.33% |
| Dec 31, 2015 | -20.49% |
| Dec 31, 2013 | -26.65% |